New York, USA – March 21, 2022 – Aptamers, known for their small size, facile chemical modification, high chemical stability, low immunogenicity, rapid tissue penetration, and engineering simplicity, are used as adaptable ligands to build efficient targeted drug delivery system, namely, aptamer-drug conjugates (ApDCs).
After several rounds of screening by SELEX, the interest aptamers with specificity for target molecules will be obtained. To ensure the efficiency of therapeutic applications, these selected aptamers must be highly stable, of moderate length, and good in pharmacokinetics. Therefore, sufficient assays are needed to characterize and evaluate the properties of the interest aptamers. Creative Biolabs has accumulated abundant experience in aptamer characterization. The featured aptamer characterization services of Creative Biolabs include but not limited to the following.
Tertiary structure analysis: Computational modeling and X-ray crystallography for predicting and determining the tertiary structure of aptamer.
Binding affinity measurement: Combination of label-free technologies such as Microscale Thermophoresis (MST), Back-scattering Interferometry (BSI), Surface Plasmon Resonance (SPR) to detect binding affinity.
Thermodynamic profiling: Isothermal Titration Calorimetry (ITC) for obtaining the full thermodynamic profile of molecular interaction to evaluate and optimize aptamers more effectively.
Competition assays: MicroScale Thermophoresis (MST) and Biolayer Interferometry (BLI) for determination of an aptamer’s ability to destroy the complex of the target molecule and its natural ligand, or to test its effect on the interaction between the target and the natural ligand.
The high specificity and selectivity of aptamers make them excellent candidates for targeted delivery of therapeutics. ApDCs not only improve the target and bioavailability of the therapeutic loaded drugs, but also significantly decrease the drug toxicity in healthy tissues. The general chemical and thermal stability and conformational reversibility of aptamers enable versatile designs of ApDCs. According to the loaded drug molecules, Creative Biolabs offers aptamer drug conjugates services widely covering proteins, peptides, antibodies, antigens, genes, enzymes, small chemicals, and so forth.
Aptamer-protein/peptide conjugates: These are the most extensively researched and applied ApDCs, of which the aptamers can be conjugated with antigens, antibodies, enzymes, and other therapeutic proteins or peptides.
Aptamer-chemotherapeutic conjugates: This off-target can be improved by conjugating the chemotherapeutics to site-specifically modified aptamers in a covalent or non-covalent manner.
Aptamer-therapeutic gene fragment conjugates: The aptamer can serve as a non-viral vector to selective deliver therapeutic gene fragments to target diseased tissues or organs.
“In our ApDCs, aptamers are used as targeting moieties to identify diseased tissues and to specifically attack them with therapeutic compounds. It is a selective and cost-effective method, and promising for addressing the limitations of the conventional drug delivery system.” said a technician from Creative Biolabs.
Explore more detailed information about aptamers-drug conjugates at https://www.creative-biolabs.com/complement-therapeutics/aptamer-drug-conjugates-development-service.htm.
With years of ample experience in drug development, Creative Biolabs is confident in providing a full portfolio of aptamer development services to promote complement therapeutics in a timely and cost-effective manner.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Country: United States